Notice: This company has been marked as potentially delisted and may not be actively trading. Audentes Therapeutics (BOLD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrends BOLD vs. CTNM, FULC, PRQR, LXRX, CYBN, NBTX, DRUG, PLRX, GNLX, and SCPHShould you be buying Audentes Therapeutics stock or one of its competitors? The main competitors of Audentes Therapeutics include Contineum Therapeutics (CTNM), Fulcrum Therapeutics (FULC), ProQR Therapeutics (PRQR), Lexicon Pharmaceuticals (LXRX), Cybin (CYBN), Nanobiotix (NBTX), Bright Minds Biosciences (DRUG), Pliant Therapeutics (PLRX), Genelux (GNLX), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical preparations" industry. Audentes Therapeutics vs. Contineum Therapeutics Fulcrum Therapeutics ProQR Therapeutics Lexicon Pharmaceuticals Cybin Nanobiotix Bright Minds Biosciences Pliant Therapeutics Genelux scPharmaceuticals Audentes Therapeutics (NASDAQ:BOLD) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings. Does the media favor BOLD or CTNM? In the previous week, Contineum Therapeutics had 3 more articles in the media than Audentes Therapeutics. MarketBeat recorded 3 mentions for Contineum Therapeutics and 0 mentions for Audentes Therapeutics. Contineum Therapeutics' average media sentiment score of 0.64 beat Audentes Therapeutics' score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Audentes Therapeutics Neutral Contineum Therapeutics Positive Does the MarketBeat Community believe in BOLD or CTNM? Audentes Therapeutics received 462 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 69.12% of users gave Audentes Therapeutics an outperform vote. CompanyUnderperformOutperformAudentes TherapeuticsOutperform Votes47069.12% Underperform Votes21030.88% Contineum TherapeuticsOutperform Votes8100.00% Underperform VotesNo Votes Which has better valuation & earnings, BOLD or CTNM? Contineum Therapeutics has higher revenue and earnings than Audentes Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAudentes TherapeuticsN/AN/A-$49.43MN/AN/AContineum Therapeutics$50M3.91$22.72MN/AN/A Is BOLD or CTNM more profitable? Contineum Therapeutics' return on equity of -49.92% beat Audentes Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Audentes TherapeuticsN/A -321.10% -40.02% Contineum Therapeutics N/A -49.92%-20.52% Do analysts rate BOLD or CTNM? Audentes Therapeutics currently has a consensus target price of $23.00, indicating a potential upside of 1,058.69%. Contineum Therapeutics has a consensus target price of $29.25, indicating a potential upside of 285.38%. Given Audentes Therapeutics' higher possible upside, analysts plainly believe Audentes Therapeutics is more favorable than Contineum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Audentes Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryContineum Therapeutics beats Audentes Therapeutics on 10 of the 12 factors compared between the two stocks. Get Audentes Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLD vs. The Competition Export to ExcelMetricAudentes TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.60M$7.06B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.7326.0419.11Price / SalesN/A306.03447.4676.36Price / CashN/A65.6738.0134.83Price / BookN/A6.717.644.62Net Income-$49.43M$138.33M$3.18B$245.85M Audentes Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLDAudentes Therapeutics2.4938 of 5 stars$1.99-13.7%$23.00+1,058.7%N/A$44.60MN/A0.00207Gap UpHigh Trading VolumeCTNMContineum Therapeutics2.919 of 5 stars$7.73+0.5%$29.25+278.4%N/A$199.28M$50M0.0031News CoveragePositive NewsFULCFulcrum Therapeutics1.8291 of 5 stars$3.69-0.5%$9.33+152.9%-59.6%$199.04M$2.81M-11.90100Upcoming EarningsNews CoveragePRQRProQR Therapeutics1.9474 of 5 stars$2.42+6.6%$8.83+265.0%+34.7%$197.67M$7.05M-7.56180LXRXLexicon Pharmaceuticals1.6589 of 5 stars$0.78+5.9%$5.00+537.0%-71.7%$193.27M$1.20M-1.05140CYBNCybin2.3423 of 5 stars$9.53+0.6%$111.50+1,070.0%N/A$192.98MN/A-1.4350Gap UpHigh Trading VolumeNBTXNanobiotix1.92 of 5 stars$4.03-3.1%$12.00+197.8%-40.5%$189.93M$39.18M0.00100DRUGBright Minds Biosciences3.9914 of 5 stars$41.80-8.6%$84.33+101.8%+1,829.8%$185.34MN/A-83.60N/AAnalyst ForecastAnalyst RevisionNews CoveragePLRXPliant Therapeutics4.5654 of 5 stars$3.04-7.6%$17.75+483.9%-80.6%$184.98M$1.58M-0.9190High Trading VolumeGNLXGenelux1.1759 of 5 stars$5.34-2.2%$18.25+241.8%-34.7%$184.44M$170,000.00-5.6210SCPHscPharmaceuticals4.2368 of 5 stars$3.68flat$15.00+307.6%-41.8%$184.15M$13.59M-1.9430Positive News Related Companies and Tools Related Companies Contineum Therapeutics Competitors Fulcrum Therapeutics Competitors ProQR Therapeutics Competitors Lexicon Pharmaceuticals Competitors Cybin Competitors Nanobiotix Competitors Bright Minds Biosciences Competitors Pliant Therapeutics Competitors Genelux Competitors scPharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BOLD) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
